ScholarIQanswers from OpenAlex & ORCID
Yi Ba
ResearcherPublications, citations & collaboration network
Yi Ba is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Yi Ba have?
ScholarIQindexed works
Yi Ba has 390 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Yi Ba have?
ScholarIQcitation count
Yi Ba has 22,514 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Yi Ba?
ScholarIQh-index
Yi Ba has an h-index of 60 in OpenAlex.
What is the i10-index of Yi Ba?
ScholarIQi10-index
Yi Ba has an i10-index of 156 in OpenAlex.
What is the ORCID of Yi Ba?
ScholarIQorcid
The ORCID for Yi Ba is on the source record.
What is the OpenAlex record for Yi Ba?
ScholarIQopenalex
The OpenAlex for Yi Ba is on the source record.
What are the most-cited papers on Yi Ba?
ScholarIQmost cited works
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Jin Li, Shukui Qin, Jianming Xu, Jianping Xiong, Changping Wu, Yuxian Bai, Wei Liu, Jiandong Tong, Yunpeng Liu, Rui‐Hua Xu, Zhehai Wang, Qiong Wang, Xuenong Ouyang, Yan Yang, Yi Ba, Jun Liang, Xiaoyan Lin, Deyun Luo, Rongsheng Zheng, Xin Wang, Guoping Sun, Liwei Wang, Leizhen Zheng, Hong Guo, Jingbo Wu, Nong Xu, Jianwei Yang, Honggang Zhang, Ying Cheng, Ningju Wang, Lei Chen, Zhining Fan, Piaoyang Sun, Hao Yu
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Hui Luo, Jin Lü, Yuxian Bai, Teng Mao, Jun Wang, Qingxia Fan, Yiping Zhang, Kuaile Zhao, Zhendong Chen, Shegan Gao, Jiancheng Li, Zhichao Fu, Kangsheng Gu, Zhihua Liu, Lin Wu, Xiaodong Zhang, Ji‐Feng Feng, Zuoxing Niu, Yi Ba, Helong Zhang, Ying Liu, Li Zhang, Xuhong Min, Jing Huang, Ying Cheng, Dong Wang, Yu Shen, Qing Yang, Jianjun Zou, Rui‐Hua Xu, ESCORT-1st Investigators, Xianglin Yuan, Dong Ma, Emily Liu, Feng Ye, Tianshu Liu, Xiuwen Wang, Likun Liu, Bing Xia, Fengming Ran, Sanyuan Sun, Zhanhui Miao, Jun Bie, Yong Gao, Junyan Yu, Li Chen, Yifu He, Wei Ren, Suxia Luo, Guangqiang Zhao, Youen Lin, Long Chen, Zhiyuan Guo, Chunhong Hu, Ying Wang, Nong Xu, Baofu Chen, Xianbao Zhan, Yuping Chen, Hongda Lu, Shukui Qin, Guolei Wang, Liming Chen, Li Bai, Jingdong Zhang
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
Jing Huang, Jianming Xu, Yun Chen, Wu Zhuang, Yiping Zhang, Zhendong Chen, Jia Chen, Helong Zhang, Zuoxing Niu, Qingxia Fan, Lizhu Lin, Kangsheng Gu, Ying Liu, Yi Ba, Zhanhui Miao, Xiaodong Jiang, Ming Zeng, Jianhua Chen, Zhichao Fu, Lu Gan, Jun Wang, Xianbao Zhan, Tianshu Liu, Zhiping Li, Lin Shen, Yongqian Shu, Tao Zhang, Qing Yang, Jianjun Zou, Suxia Luo, Feng Peng, Gang Wu, Nong Xu, Lin Zhao, Dong Ma, Shukui Qin, Wei Ren, Enxiao Li, Hongda Lu, Yueyin Pan, Jianping Xiong, Ying Yuan, Yuxian Bai, Lei Chen, Yi Hu, Li Zhang, Yong Gao
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial
Rui‐Hua Xu, Kei Muro, Satoshi Morita, Satoru Iwasa, Sae Won Han, Wei Wang, Masahito Kotaka, Masato Nakamura, Joong Bae Ahn, Yan‐Hong Deng, Takeshi Kato, Sang‐Hee Cho, Yi Ba, Hiroshi Matsuoka, Keun‐Wook Lee, Tao Zhang, Yasuhide Yamada, Junichi Sakamoto, Young Suk Park, Tae Won Kim